You can access any of the podium or poster presentations’ abstracts by searching for it below. For the 2026 FIP world congress in Montreal, presentations and summaries from invited speakers are available below, while abstracts are published in the Pharmacy Education Journal (PEJ) here.
Export this Abstract | Print this Abstract |
Add to my preferred Abstracts list |
My preferred Abstracts list (0) |
Back to Search
Pharmacokinetic characterization of krca-0008 as a novel potent and selective anaplastic lymphoma kinase inhibitor for anticancer treatment
- In: Poster presentation
- At: Seoul (South Korea) (2017)
- Type: Poster
- Poster code: POS-PAA-001
- By: AHN, Sung-Hoon (Kangwon National University, College of Pharmacy, Chuncheon, Korea, Republic Of)
- Co-author(s): Sung-Hoon Ahn: College of Pharmacy, Kangwon National University, Chuncheon, Korea, Republic Of
- Abstract:
Background
KRCA-0008, bis-ortho-alkoxy-para-piperazinesubstituted-2,4-dianilinopyrimidines, has been under development as a potent and selective Anaplastic lymphoma kinase (ALK) and Ack1 dual inhibitor for anti-cancer treatment. KRCA-0008 has in vivo efficacy with a modest tumor growth inhibition in xenograft mice model bearing H3122 human lung.. The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress.
Please login
Last update 23 September 2026